enGene (ENGN) Q1 2026 earnings summary

Executive summary

• Focused on developing genetic medicines for NMIBC, with lead candidate detalimogene voraplasmid in pivotal Phase 2 trials and LEGEND pivotal cohort update planned for spring 2026; BLA submission targeted for 2H 2026.

• No products approved or revenue generated; operations funded by equity, debt, and warrant issuances.

• Cash and marketable securities totaled $312.5M as of January 31, 2026, expected to fund operations into 2H 2028.

• Net loss increased to $29.8M for the quarter ended January 31, 2026, compared to $24.6M in the prior year period.

• Expanded $125M debt facility and $140.1M raised in a November 2025 public offering provide financial flexibility for detalimogene development.

Financial highlights

• Research and development expenses rose to $22.3M, and total operating expenses for Q1 2026 were $31.2M, up from $26.6M in Q1 2025, driven by higher personnel and clinical operations costs.

• General and administrative expenses increased to $8.9M, mainly due to increased headcount and facilities costs.

• Net loss per share was $0.44 (basic and diluted), compared to $0.48 in the prior year.

• Net cash used in operating activities was $28.9M; net cash provided by financing activities was $141.7M, primarily from a public offering and new term loan.

• Cash, cash equivalents, and marketable securities totaled $312.5M as of January 31, 2026, up from $202.3M at October 31, 2025.

Outlook and guidance

• Cash runway expected to extend into the second half of 2028, supporting ongoing clinical development and planned BLA submission.

• Plans to submit a Biologics License Application for detalimogene in the second half of 2026.

• Anticipates continued operating losses and need for substantial additional funding to support ongoing and future development.

• Anticipated milestones include LEGEND pivotal cohort update in spring 2026, 12-month data in 2H 2026, and potential commercial launch in 2027 pending FDA approval.